A detailed history of Ameriprise Financial Inc transactions in Erasca, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 20,928 shares of ERAS stock, worth $54,831. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,928
Previous 173,803 87.96%
Holding current value
$54,831
Previous $410,000 86.1%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.17 - $3.28 $331,738 - $501,429
-152,875 Reduced 87.96%
20,928 $57,000
Q2 2024

Aug 14, 2024

BUY
$1.79 - $2.63 $311,107 - $457,101
173,803 New
173,803 $410,000
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.49 $82,179 - $122,530
49,209 New
49,209 $104,000
Q2 2023

Aug 14, 2023

BUY
$2.57 - $3.3 $57,393 - $73,695
22,332 Added 219.48%
32,507 $89,000
Q1 2023

May 15, 2023

BUY
$2.74 - $4.44 $27,879 - $45,177
10,175 New
10,175 $30,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $320M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.